These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 33220820)

  • 41. Cost-effectiveness of novel therapies for overactive bladder.
    Mayr CA; Shepherd JP
    Expert Rev Pharmacoecon Outcomes Res; 2014 Aug; 14(4):527-35. PubMed ID: 24809616
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intravesical Botox for Overactive Bladder: How to Minimize Complications and Manage Failures.
    Apostolidis A; Papaefstathiou E; Gatsos S
    Curr Drug Targets; 2020; 21(15):1527-1536. PubMed ID: 32564753
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Current management of refractory overactive bladder.
    Chen LC; Kuo HC
    Low Urin Tract Symptoms; 2020 May; 12(2):109-116. PubMed ID: 32073742
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [First-line treatment for non-neurogenic overactive bladder].
    Gamé X; Phé V
    Prog Urol; 2020 Nov; 30(14):904-919. PubMed ID: 33220819
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Botulinum toxin A for the Treatment of Overactive Bladder.
    Hsieh PF; Chiu HC; Chen KC; Chang CH; Chou EC
    Toxins (Basel); 2016 Feb; 8(3):. PubMed ID: 26938559
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An overview of treatment of overactive bladder syndrome in women.
    Allahdin S; Oo N
    J Obstet Gynaecol; 2012 Apr; 32(3):217-21. PubMed ID: 22369391
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical application of intravesical botulinum toxin type A for overactive bladder and interstitial cystitis.
    Chen JL; Kuo HC
    Investig Clin Urol; 2020 Feb; 61(Suppl 1):S33-S42. PubMed ID: 32055752
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bladder instillation of liposome encapsulated onabotulinumtoxina improves overactive bladder symptoms: a prospective, multicenter, double-blind, randomized trial.
    Chuang YC; Kaufmann JH; Chancellor DD; Chancellor MB; Kuo HC
    J Urol; 2014 Dec; 192(6):1743-9. PubMed ID: 25046622
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and tolerance of botulinum toxin injections after sacral nerve stimulation failure for idiopathic overactive bladder.
    Baron M; Perrouin-Verbe MA; Lacombe S; Paret F; Le Normand L; Cornu JN
    Neurourol Urodyn; 2020 Mar; 39(3):1012-1019. PubMed ID: 32108383
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The management of overactive bladder: percutaneous tibial nerve stimulation, sacral nerve stimulation, or botulinum toxin?
    Tubaro A; Puccini F; De Nunzio C
    Curr Opin Urol; 2015 Jul; 25(4):305-10. PubMed ID: 26049873
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sacral neuromodulation for refractory overactive bladder after prior intravesical onabotulinumtoxinA treatment.
    Hoag N; Plagakis S; Pillay S; Edwards AW; Gani J
    Neurourol Urodyn; 2017 Jun; 36(5):1377-1381. PubMed ID: 27612039
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Objective and subjective improvement in children with idiopathic detrusor overactivity after intravesical botulinum toxin injection: A preliminary report.
    Al Edwan GM; Mansi HH; Atta ONM; Shaath MM; Al Adwan R; Mahafza W; Afram KM; Ababneh O; Al Adwan D; Muheilan MM
    J Pediatr Surg; 2019 Mar; 54(3):595-599. PubMed ID: 29887168
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Refractory overactive bladder patients who chose sacral neuromodulation therapy after failed OnabotulinumtoxinA treatment: A systematic review and meta-analysis.
    Yang G; Xu Y; Qu G; Zhang Y
    PLoS One; 2020; 15(3):e0230355. PubMed ID: 32226049
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The second-line management of idiopathic overactive bladder: what is the place of sacral neuromodulation and botulinum toxin-A in contemporary practice?
    Chapple C; De Ridder D
    BJU Int; 2009 Nov; 104(9):1188-90. PubMed ID: 19681899
    [No Abstract]   [Full Text] [Related]  

  • 55. [Tibial nerve transcutaneous stimulation for refractory idiopathic overactive bladder in children and adolescents].
    Bouali O; Even L; Mouttalib S; Moscovici J; Galinier P; Game X
    Prog Urol; 2015 Sep; 25(11):665-72. PubMed ID: 26022237
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Urinary Biomarkers in Women with Refractory Urgency Urinary Incontinence Randomized to Sacral Neuromodulation versus OnabotulinumtoxinA Compared to Controls.
    Richter HE; Moalli P; Amundsen CL; Malykhina AP; Wallace D; Rogers R; Myers D; Paraiso M; Albo M; Shi H; Nolen T; Meikle S; Word RA;
    J Urol; 2017 Jun; 197(6):1487-1495. PubMed ID: 28089729
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of Overactive Bladder-Wet Syndrome on Female Sexual Function: A Systematic Review and Meta-Analysis.
    Balzarro M; Rubilotta E; Mancini V; Trabacchin N; Oppezzi L; Li Marzi V; Fusco F; Serati M
    Sex Med Rev; 2019 Oct; 7(4):565-574. PubMed ID: 31326358
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Botulinum toxin-A injections into neurogenic overactive bladder--to include or exclude the trigone? A prospective, randomized, controlled trial.
    Abdel-Meguid TA
    J Urol; 2010 Dec; 184(6):2423-8. PubMed ID: 20952003
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Idiopathic overactive bladder and BOTOX(®): Literature review].
    Gamé X; Karsenty G; Ruffion A; Amarenco G; Ballanger P; Chartier-Kastler E; Cosson M; Costa P; Fatton B; Deffieux X; Haab F; Hermieu JF; Le Normand L; Saussine C; Denys P
    Prog Urol; 2015 Jun; 25(8):461-73. PubMed ID: 25662706
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Treatment of non-neurogenic masculine urinary incontinence due to overactive bladder: a review by the LUTS committee of the French Urological Association].
    Lebdai S; Haillot O; Azzouzi AR; Benchikh A; Campeggi A; Cornu JN; Delongchamps NB; Dumonceau O; Faix A; Fourmarier M; Lukacs B; Mathieu R; Misrai V; Robert G; de La Taille A; Descazeaud A
    Prog Urol; 2014 Jul; 24(9):588-94. PubMed ID: 24975794
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.